ORPHA:314701
Primary systemic amyloidosis
Also known as: Systemic AL amyloidosis
Publications
8,867
97.2th percentile
Trials
56
Interventional, condition-specific
Researchers
1,141
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017816
- UMLS:C0281479
- NCIT:C8299
Additional Mondo synonyms (3)
systemic AL amyloidosis · systemic Immunoglobulin Light chain amyloidosis · systemic amyloidosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
8,867 matched papers (4,258 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
56 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
8,867
8,867 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
8,867 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
4,258 in the last 10 years · high confidence · 97.2th percentile (publications denominator)
Phrase hits: 8,867 · MeSH hits: 0
Who's working on it?
1,141
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Cuddy SAM4 papers · 2026
Cardiac Amyloidosis Program, Brigham and Women's Hospital, Boston, MA, USA.
Papers in Europe PMC - 02Dispenzieri A4 papers · 2026
Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: dispenzieri.angela@mayo.edu.
Papers in Europe PMC - 03Dorbala S4 papers · 2026
Department of Medicine and Radiology, CV Imaging Program, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Papers in Europe PMC - 04Hegenbart U4 papers · 2026
Medizinische Klinik V: Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland. ute.hegenbart@med.uni-heidelberg.de.
Papers in Europe PMC - 05Khouri J4 papers · 2026
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Papers in Europe PMC - 06
- 07Raza S4 papers · 2026
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
Papers in Europe PMC - 08Sanchorawala V4 papers · 2026
Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Papers in Europe PMC - 09Aus dem Siepen F3 papers · 2026
Amyloidose-Zentrum, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Papers in Europe PMC - 10Bianchi G3 papers · 2026
Amyloidosis Program, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
56
interventional trials for this specific condition
56 interventional trials matched this specific condition name; 7 currently recruiting in our sample. 313 trials are registered for amyloidosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
56 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.3th percentile).
high confidence · 97.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
56 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06699394·RECRUITING·Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Conditions: AL Amyloidosis·Matched via name phrase
- NCT06342466·RECRUITING·Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Conditions: Systemic Amyloidosis·Matched via name phrase
- NCT07687004·NOT YET RECRUITING·Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
Conditions: Multiple Myeloma (MM)·Matched via name phrase
- NCT05951816·RECRUITING·A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Conditions: Systemic Amyloidosis·Matched via name phrase
- NCT05758493·RECRUITING·Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Conditions: Amyloidosis · Transthyretin Amyloidosis·Matched via name phrase
- NCT07709715·NOT YET RECRUITING·A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Conditions: Light Chain (AL) Amyloidosis·Matched via name phrase
- NCT07624760·NOT YET RECRUITING·Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
Conditions: Monoclonal Gammopathy · Monoclonal Gammopathy of Undetermined Significance (MGUS) · Multiple Myeloma · AL Amyloidosis·Matched via name phrase
Broader category: amyloidosis
313
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05019027·ENROLLING BY INVITATION·N-of-1 for Beta-Blockers in Cardiac Amyloidosis
Conditions: Cardiac Amyloidosis · Heart Diseases · TTR Cardiac Amyloidosis·Matched via name phrase
- NCT06022939·RECRUITING·Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Conditions: AL Amyloidosis·Matched via name phrase
- NCT07266116·RECRUITING·Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Conditions: Systemic Light Chain Amyloidosis·Matched via name phrase
- NCT07055724·NOT YET RECRUITING·Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Conditions: AL Amyloidosis·Matched via name phrase
- NCT07052903·RECRUITING·TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Conditions: Transthyretin Amyloidosis With Cardiomyopathy·Matched via name phrase
- NCT06629818·RECRUITING·Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
Conditions: Light Chain (AL) Amyloidosis·Matched via name phrase
- NCT07638683·RECRUITING·A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Conditions: Multiple Myeloma · AL Amyloidosis·Matched via name phrase
- NCT07504289·NOT YET RECRUITING·CAR-NK Therapy for Cardiac Amyloidosis
Conditions: Light Chain Cardiac Amyloidosis·Matched via name phrase
- NCT06907186·RECRUITING·An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy
Conditions: Hereditary Transthyretin Amyloidosis·Matched via name phrase
- NCT06998875·RECRUITING·A Prospective Cohort Study on Primary Cutaneous Amyloidosis
Conditions: Primary Cutaneous Amyloidosis·Matched via name phrase
- NCT04991103·RECRUITING·Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Conditions: Multiple Myeloma · Amyloidosis·Matched via name phrase
- NCT04935021·RECRUITING·Clinical Study of ATTR-CM
Conditions: Transthyroxine Amyloidosis Cardiomyopathy·Matched via name phrase
- NCT04535349·RECRUITING·Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
Conditions: Amyloidosis Transthyretin·Matched via name phrase
- NCT07250269·RECRUITING·Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Conditions: Relapsed/Refractory AL Amyloidosis·Matched via name phrase
- NCT04667494·RECRUITING·Ultrasound Therapy In Cardiac Amyloidosis
Conditions: Amyloidosis Cardiac·Matched via name phrase
Observational and natural-history studies
13 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06866912·RECRUITING·Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
Conditions: Cardiomyopathy·Matched via name phrase
- NCT07689331·RECRUITING·Hungarian National Systemic Amyloidosis Registry
Conditions: Systemic Amyloidosis · ATTR Amyloidosis · AL Amyloidosis · Amyloid Cardiomyopathy·Matched via name phrase
- NCT06627309·RECRUITING·Rapid dFLC Response Predict CHR in AL Amyloidosis
Conditions: Systemic AL Amyloidosis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary systemic amyloidosis" OR "Systemic AL amyloidosis" OR "systemic Immunoglobulin Light chain amyloidosis" OR "systemic amyloidosis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary systemic amyloidosis" OR "Systemic AL amyloidosis" OR "systemic Immunoglobulin Light chain amyloidosis" OR "systemic amyloidosis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 56 interventional · 13 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"amyloidosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:12:39.259Z
